CD4 and graft versus host disease: aGVHD in 2/2 at 3 × 104/kg; aGVHD grade I not requiring systemic treatment at 1 × 104/kg/month but high relapse rate; GVHD in all patients with dose-escalated DLI or therapeutic DLI. CD4 count ≥ 100 /μL at 6–14 months.